Huntington disease skeletal muscle is hyperexcitable owing to chloride and potassium channel dysfunction
- PMID: 23671115
- PMCID: PMC3670332
- DOI: 10.1073/pnas.1220068110
Huntington disease skeletal muscle is hyperexcitable owing to chloride and potassium channel dysfunction
Abstract
Huntington disease is a progressive and fatal genetic disorder with debilitating motor and cognitive defects. Chorea, rigidity, dystonia, and muscle weakness are characteristic motor defects of the disease that are commonly attributed to central neurodegeneration. However, no previous study has examined the membrane properties that control contraction in Huntington disease muscle. We show primary defects in ex vivo adult skeletal muscle from the R6/2 transgenic mouse model of Huntington disease. Action potentials in diseased fibers are more easily triggered and prolonged than in fibers from WT littermates. Furthermore, some action potentials in the diseased fibers self-trigger. These defects occur because of decreases in the resting chloride and potassium conductances. Consistent with this, the expression of the muscle chloride channel, ClC-1, in Huntington disease muscle was compromised by improper splicing and a corresponding reduction in total Clcn1 (gene for ClC-1) mRNA. Additionally, the total Kcnj2 (gene for the Kir2.1 potassium channel) mRNA was reduced in disease muscle. The resulting muscle hyperexcitability causes involuntary and prolonged contractions that may contribute to the chorea, rigidity, and dystonia that characterize Huntington disease.
Keywords: channelopathy; electrophysiology; myopathy; myotonia; trinucleotide repeat.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Progressive Cl- channel defects reveal disrupted skeletal muscle maturation in R6/2 Huntington's mice.J Gen Physiol. 2017 Jan;149(1):55-74. doi: 10.1085/jgp.201611603. Epub 2016 Nov 29. J Gen Physiol. 2017. PMID: 27899419 Free PMC article.
-
Mechanisms of altered skeletal muscle action potentials in the R6/2 mouse model of Huntington's disease.Am J Physiol Cell Physiol. 2020 Jul 1;319(1):C218-C232. doi: 10.1152/ajpcell.00153.2020. Epub 2020 May 20. Am J Physiol Cell Physiol. 2020. PMID: 32432924 Free PMC article.
-
Depressed Synaptic Transmission and Reduced Vesicle Release Sites in Huntington's Disease Neuromuscular Junctions.J Neurosci. 2017 Aug 23;37(34):8077-8091. doi: 10.1523/JNEUROSCI.0313-17.2017. Epub 2017 Jul 19. J Neurosci. 2017. PMID: 28724748 Free PMC article.
-
Role of physiological ClC-1 Cl- ion channel regulation for the excitability and function of working skeletal muscle.J Gen Physiol. 2016 Apr;147(4):291-308. doi: 10.1085/jgp.201611582. J Gen Physiol. 2016. PMID: 27022190 Free PMC article. Review.
-
Channelopathies of skeletal muscle excitability.Compr Physiol. 2015 Apr;5(2):761-90. doi: 10.1002/cphy.c140062. Compr Physiol. 2015. PMID: 25880512 Free PMC article. Review.
Cited by
-
ClC-1 chloride channels: state-of-the-art research and future challenges.Front Cell Neurosci. 2015 Apr 27;9:156. doi: 10.3389/fncel.2015.00156. eCollection 2015. Front Cell Neurosci. 2015. PMID: 25964741 Free PMC article. Review.
-
Huntingtin regulates calcium fluxes in skeletal muscle.J Gen Physiol. 2023 Jan 2;155(1):e202213103. doi: 10.1085/jgp.202213103. Epub 2022 Nov 21. J Gen Physiol. 2023. PMID: 36409218 Free PMC article.
-
A mouse model of Huntington's disease shows altered ultrastructure of transverse tubules in skeletal muscle fibers.J Gen Physiol. 2021 Apr 5;153(4):e202012637. doi: 10.1085/jgp.202012637. J Gen Physiol. 2021. PMID: 33683318 Free PMC article.
-
Potassium channel dysfunction in neurons and astrocytes in Huntington's disease.CNS Neurosci Ther. 2018 Apr;24(4):311-318. doi: 10.1111/cns.12804. Epub 2018 Jan 27. CNS Neurosci Ther. 2018. PMID: 29377621 Free PMC article. Review.
-
Progressive Cl- channel defects reveal disrupted skeletal muscle maturation in R6/2 Huntington's mice.J Gen Physiol. 2017 Jan;149(1):55-74. doi: 10.1085/jgp.201611603. Epub 2016 Nov 29. J Gen Physiol. 2017. PMID: 27899419 Free PMC article.
References
-
- Bett JS, Bates GP, Hockly E. Molecular pathogenesis and therapeutic targets in Huntington’s disease. In: Wells RD, Ashizawa T, editors. Genetic Instabilities and Neurological Diseases. 2nd Ed. Boston: Elsevier/Academic Press; 2006. pp. 223–249.
-
- Lo DC, Hughes RE. Neurobiology of Huntington’s Disease: Applications to Drug Discovery. Boca Raton, FL: CRC/Taylor & Francis Group; 2010. p. 312. - PubMed
-
- Arenas J, et al. Complex I defect in muscle from patients with Huntington’s disease. Ann Neurol. 1998;43(3):397–400. - PubMed
-
- Busse ME, Hughes G, Wiles CM, Rosser AE. Use of hand-held dynamometry in the evaluation of lower limb muscle strength in people with Huntington’s disease. J Neurol. 2008;255(10):1534–1540. - PubMed
-
- Lodi R, et al. Abnormal in vivo skeletal muscle energy metabolism in Huntington’s disease and dentatorubropallidoluysian atrophy. Ann Neurol. 2000;48(1):72–76. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
